Click here to receive MS news via e-mail
VANCOUVER -- Natalizumab (Tysabri) didn't slow disability progression in patients with secondary progressive multiple sclerosis (SPMS), researchers reported here.
The ASCEND trial missed its primary endpoint of reducing progression as measured by a composite endpoint assessing disability unrelated to relapses, Deborah Steiner, MD, of Biogen, reported during the emerging science session at the American Academy of Neurology meeting here.
"There's a striking contrast between the lack of effect on ambulatory function as measured by the timed 25-foot walk test, and the effects on upper extremity function as measured by the 9-hole peg test," she said.
There are currently no approved therapies for primary progressive or secondary progressive MS -- although data reported here on ocrelizumab, an investigational B-cell targeting therapy by Roche/Genentech, suggested the drug has some efficacy in primary progressive disease.
MS Views and News
Providing educational information and resources for those affected by MS
Keep current with Multiple Sclerosis news and information